April 2014
Volume 55, Issue 13
ARVO Annual Meeting Abstract  |   April 2014
Optical Coherence Tomography as an endpoint in nonhuman primate models of ocular disease
Author Affiliations & Notes
  • Robin J Goody
    RxGen, Inc, Hamden, CT
  • Rohn Brookes
    RxGen, Inc, Hamden, CT
  • Alex A Lewis
    RxGen, Inc, Hamden, CT
  • Steve Henry
    RxGen, Inc, Hamden, CT
  • Mike Struharik
    RxGen, Inc, Hamden, CT
  • Steve Whittaker
    RxGen, Inc, Hamden, CT
  • Wenzheng Hu
    RxGen, Inc, Hamden, CT
  • Matthew S Lawrence
    RxGen, Inc, Hamden, CT
  • Footnotes
    Commercial Relationships Robin Goody, RxGen (E); Rohn Brookes, RxGen (E); Alex Lewis, RxGen (E); Steve Henry, RxGen (E); Mike Struharik, RxGen (E); Steve Whittaker, RxGen (E); Wenzheng Hu, RxGen (E); Matthew Lawrence, RxGen (E)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 2108. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Robin J Goody, Rohn Brookes, Alex A Lewis, Steve Henry, Mike Struharik, Steve Whittaker, Wenzheng Hu, Matthew S Lawrence; Optical Coherence Tomography as an endpoint in nonhuman primate models of ocular disease. Invest. Ophthalmol. Vis. Sci. 2014;55(13):2108.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: To define optical coherence tomography (OCT) derived measures of retinal anatomy in the healthy African green monkey (AGM) eye and to evaluate the utility of these measurements in nonhuman primate models of ocular disease.

Methods: Thirteen male and fourteen female adult AGMs were examined using a Heidelberg Spectralis OCT+ instrument as part of standard prescreening of animals with healthy eyes prior to induction of ophthalmic disease models. Two male and one female AGM from this cohort were used in a study characterizing photoembolism-induced non-arteritic ischemic optic neuropathy (NAION) in the AGM with OCT employed as a primary endpoint to evaluate experimental NAION. Retinal nerve fiber layer (RNFL) and full retinal thickness (RT) measurements were performed using automated tools within the Spectralis software. Circumpapillary OCT scans were performed centered on the optic nerve head (ONH) for RNFL measures and on the fovea for RT assessments using 1, 3 and 6 mm diameter scans. RNFL was measured serially in animals employed in the NAION study. All work was conducted in compliance with the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research.

Results: No significant differences in RT or RNFL thickness were observed between males and females during prescreening. Mean RT measures were 276±19µm in the central retina and ranged from 318 to 370µm in the outer segments and 350 to 369µm in inner portions of superior, inferior, temporal and nasal quadrants. Mean global RNFL thickness measures in the healthy ONH were 103±6µm with values ranging from a low of 73µm in the outer nasal area to a high of 150µm in the inner temporal region. In animals receiving a photoembolism procedure to induce experimental NAION significant increases in RNFL thickness were observed initially (104±1µm at baseline versus 178±21µm at week 1) in response to photoembolism, followed by thinning to sub-baseline measures (65±8µm) by week seven, reflecting retinal ganglion cell loss.

Conclusions: Application of OCT examinations and measurement of RNFL and RT dimensions offers a reliable, high throughput addition to general animal prescreening required to define suitability of animals for enrollment in ophthalmic studies. Measurement of RNFL or RT can be employed to evaluate progression and resolution of experimentally-induced disease and to evaluate efficacy of novel therapeutic interventions.

Keywords: 551 imaging/image analysis: non-clinical • 637 pathology: experimental • 688 retina  

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.